ClinicalTrials.govpublic full text
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
metastatic hepatocellular carcinoma, local advanced hepatocellular carcinoma, alpha-fetoprotein (afp)-producing gastric cancer, extragonadal yolk sac tumors, glypican-3 (gpc3)-positive squamous non-small cell lung cancer, gpc-3, gpc3-positive squamous non-small cell lung cancer, bgb-b2033, tislelizumab, hepatocellular carcinoma, bevacizumab, interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 875169
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.